Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tri-Do-Re: Triple-dose TB Retreatment Regimen
NCT04260477Phase 3Recruiting
- Sponsor
- Institute of Tropical Medicine Antwerp
- Start
- Mar 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifampicin, isoniazid in Tuberculosis (TB), sponsored by Institute of Tropical Medicine Antwerp. Started Mar 2021; status: recruiting.
02
Drugs
rifampicinisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04260477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260477.